Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of HR091506 Batches in Healthy Subjects
NCT07076459Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR091506 in gout and hyperuricemia (6 arms), sponsored by Hengrui. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and 2 more. Started Jul 2025; status: completed.
02
Drugs
HR091506
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT07076459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076459.